Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026

Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet age-related macular degeneration are scheduled for their first scientific presentation at AAO 2026. Additional presentations will include Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy and Phase 1b APEX data for KSI-101 in macular disease; no results or numerical outcomes are provided.